Former General Surgeon Joins Local Diagnostic Technology Company as Advisor | Business Observer
SARASOTA – After serving as the 20th Surgeon General of the United States, Dr. Jerome Adams joins Lumos Diagnostic as a Strategic Healthcare Advisor.
Lumos, a rapid point-of-service (POC) diagnostic technology company founded in Lakewood Ranch, also appointed Adams to the company’s medical advisory board, according to a statement. As a strategic healthcare advisor, Adams will provide advice on the effective deployment of POC diagnostic technologies, with the first task being the launch of FebriDx, a new finger blood test that can differentiate whether a person has a bacterial infection or viral.
“The pressing health challenges of the past 18 months have highlighted the importance of diagnostic testing as one of the key tools in addressing both the current pandemic and the looming pandemic of antimicrobial resistance,” Adams said in the press release. “We need to anticipate these problems with a truly accessible outpatient solution. “
“Lumos found a match in our passion for public health in Dr. Adams,” added Dr. Rob Sambursky, president and CEO of Lumos, in the release. “Together, we intend to have a significant impact on millions of patients each year by improving global access to innovative and cost-effective rapid diagnostic test solutions. “
While Adams was a general surgeon between 2017 and 2021, he served on the front lines of the US response to COVID-19. He has also worked to combat the opioid epidemic, increasing rates of chronic disease, the impacts of increasing suicide rates, promoting maternal health and helping businesses promote community health and equitable access to health care resources, the release said, He is currently an assistant professor of clinical anesthesia at Indiana University and practices as a staff anesthesiologist at Eskenazi Health.
Lumos Diagnostics, a Carlsbad, California-based company merged with Lakewood Ranch-based RPS Diagnostics in 2019. Following the merger, the company received a $ 15 million investment from Planet Innovation, a company Australian health technology innovation and commercialization. Lumos is a subsidiary of Planet Innovation. The investment was made to support the international business expansion of the FebriDX test.